fda compounding semaglutide enforcement november 2025 news is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified The FDA has issued warning
Description
28 , 40 The sitagliptin/metformin combination (Janumet) may be most appropriate in patients close to their HbA 1c goal who are taking dual antihyperglycemic agents or in those experiencing hypoglycemia with their current regimen
Emergency Foods Cheat Sheet Nausea-safe, no-prep ideas to sip, snack, or order when everything feels impossible
A moderate dinner with protein and vegetables works well
Patients frequently report clearer thinking, steadier energy, and less brain fog, which can have a meaningful impact on quality of life as part of a broader longevity strategy
